Published • loading... • Updated
Miro clears TGA audit ahead of Crohn’s disease trial
The audit clears the way for scale-up of StemSmart production and a phase II trial, after early data showed a 78% clinical response rate.
Summary by Sydney Morning Herald
4 Articles
4 Articles
Sydney Morning Herald+3 Reposted by 3 other sources
Miro clears TGA audit ahead of Crohn’s disease trial
Miro Sciences has cleared a TGA manufacturing hurdle for its Crohn’s trial, with the regulator inspecting its partner’s facility ahead of a planned Phase 2 study for its StemSmart cell therapy.
·North Sydney, Australia
Read Full ArticleCoverage Details
Total News Sources4
Leaning Left3Leaning Right1Center0Last UpdatedBias Distribution75% Left
Bias Distribution
- 75% of the sources lean Left
75% Left
L 75%
R 25%
Factuality
To view factuality data please Upgrade to Premium
